CYP2C19- and CYP3A4-Dependent Omeprazole Metabolism in West Mexicans

This publication has 26 references indexed in Scilit:

• Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
  British Journal of Clinical Pharmacology, 2001
• Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype*
  Clinical Pharmacology & Therapeutics, 1998
• Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
  European Journal of Clinical Pharmacology, 1997
• The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study*
  Clinical Pharmacology & Therapeutics, 1995
• Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.
  British Journal of Clinical Pharmacology, 1995
• Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects
  Pharmacogenetics, 1992
• Omeprazole
  Digestive Diseases and Sciences, 1991
• Clinical Pharmacology of Omeprazole
  Clinical Pharmacokinetics, 1991
• Omeprazole: Pharmacokinetics and Metabolism in Man
  Scandinavian Journal of Gastroenterology, 1989
• Omeprazole
  Drugs, 1986